VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 22 filers reported holding VECTIVBIO HLDG AG in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $5,872,372 | -7.5% | 682,834 | -7.4% | 0.22% | -6.7% |
| Q4 2022 | $6,351,631 | +39.9% | 737,704 | -2.5% | 0.24% | +29.0% |
| Q3 2022 | $4,539,000 | +11.1% | 756,502 | 0.0% | 0.19% | +15.5% |
| Q2 2022 | $4,085,000 | +14.9% | 756,502 | 0.0% | 0.16% | +28.8% |
| Q1 2022 | $3,556,000 | -4.3% | 756,502 | 0.0% | 0.12% | +4.2% |
| Q4 2021 | $3,714,000 | -30.9% | 756,502 | 0.0% | 0.12% | -30.6% |
| Q3 2021 | $5,372,000 | +217.7% | 756,502 | +421.7% | 0.17% | +214.5% |
| Q2 2021 | $1,691,000 | – | 145,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 5,255,484 | $44,724,170 | 11.87% |
| TCG Crossover Management, LLC | 3,113,600 | $26,496,736 | 5.16% |
| CAXTON CORP | 156,651 | $1,345,549 | 3.40% |
| VR Adviser, LLC | 1,866,000 | $15,879,660 | 3.10% |
| Novo Holdings A/S | 3,610,461 | $30,725,023 | 2.03% |
| Cormorant Asset Management, LP | 2,536,617 | $21,587 | 1.42% |
| Vivo Capital, LLC | 2,333,300 | $19,856,383 | 1.38% |
| Orbimed Advisors | 5,156,561 | $43,882,334 | 0.86% |
| Frazier Life Sciences Management, L.P. | 1,352,199 | $11,628,911 | 0.84% |
| Bpifrance SA | 2,806,217 | $23,880,907 | 0.61% |